Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Cremolini

Showing results (61-70 of 284) with videos related to

Pageof 29
Sort By:
European Thyroid Journal|May 27, 2022
Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockadeAlessandro Brancatella, Laura Pierotti, Nicola Viola, et al.
Clinical Colorectal Cancer|September 10, 2011
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimenLorenzo Fornaro, Enrico Vasile, Gianluca Masi, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2021
Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancerHiroyuki Arai, Joshua Millstein, Fotios Loupakis, et al.
Frontiers in Oncology|December 12, 2022
Surgery combined with intra-operative microwaves ablation for the management of colorectal cancer liver metastasis: A case-matched analysis and evaluation of recurrencesSimone Guadagni, Federica Marmorino, Niccolò Furbetta, et al.
Cancers|October 17, 2020
Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer PatientsNico B Volz, Diana L Hanna, Sebastian Stintzing, et al.
The Pharmacogenomics Journal|February 5, 2021
Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancerMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
Clinical Colorectal Cancer|May 22, 2026
Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal CancerLisa Salvatore, Marwan Fakih, Yasutoshi Kuboki, et al.
Cancers|November 27, 2021
Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge StrategyDavide Ciardiello, Vincenzo Famiglietti, Stefania Napolitano, et al.
British Journal of Cancer|June 21, 2017
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximabLaura Demurtas, Marco Puzzoni, Riccardo Giampieri, et al.
The Lancet. Oncology|August 13, 2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trialGianluca Masi, Fotios Loupakis, Lisa Salvatore, et al.
Pageof 29

Showing results (61-70 of 284) with videos related to

Sort By:
Pageof 29
European Thyroid Journal|May 27, 2022
Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockadeAlessandro Brancatella, Laura Pierotti, Nicola Viola, et al.
Clinical Colorectal Cancer|September 10, 2011
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimenLorenzo Fornaro, Enrico Vasile, Gianluca Masi, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2021
Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancerHiroyuki Arai, Joshua Millstein, Fotios Loupakis, et al.
Frontiers in Oncology|December 12, 2022
Surgery combined with intra-operative microwaves ablation for the management of colorectal cancer liver metastasis: A case-matched analysis and evaluation of recurrencesSimone Guadagni, Federica Marmorino, Niccolò Furbetta, et al.
Cancers|October 17, 2020
Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer PatientsNico B Volz, Diana L Hanna, Sebastian Stintzing, et al.
The Pharmacogenomics Journal|February 5, 2021
Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancerMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
Clinical Colorectal Cancer|May 22, 2026
Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal CancerLisa Salvatore, Marwan Fakih, Yasutoshi Kuboki, et al.
Cancers|November 27, 2021
Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge StrategyDavide Ciardiello, Vincenzo Famiglietti, Stefania Napolitano, et al.
British Journal of Cancer|June 21, 2017
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximabLaura Demurtas, Marco Puzzoni, Riccardo Giampieri, et al.
The Lancet. Oncology|August 13, 2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trialGianluca Masi, Fotios Loupakis, Lisa Salvatore, et al.
Pageof 29